1. World Health Organization. 2015 progress report on the global plan towards the elimination of new HIV infections among children and keeping their mothers alive. Geneva: World Health Organization; 2015 [cited 2017 Oct 20]. Available from: http://www.unaids.org/sites/default/files/media_asset/JC2774_2015ProgressReport_GlobalPlan_en.pdf.
2. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet. 2004;364(9441):1236–43. doi: 10.1016/S0140-6736(04)17140-7 15464184
3. Ghadrshenas A, Ben Amor Y, Chang J, Dale H, Sherman G, Vojnov L. Improved access to early infant diagnosis is a critical part of a child-centric prevention of mother-to-child transmission agenda. AIDS. 2013;27(Supp 2):S197–205.
4. Mayaux M-J, Burgard M, Teglas J, Cottalorda J, Krivine A, Puel J, et al. Neonatal characteristics in rapidly progressive perinatally acquired HIV-1 disease. JAMA. 1996;275(8):606–10. 8594241
5. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359(21):2233–44. doi: 10.1056/NEJMoa0800971 19020325
6. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2013 [cited 2017 Oct 20]. Available from: http://www.who.int/hiv/pub/guidelines/arv2013/download/en/index.html.
7. World Health Organization. Consolidated guidelines on HIV testing services. 5Cs: consent, confidentiality, counselling, correct results, and connection. Geneva: World Health Organization; 2015.
8. Simpson BJ, Andiman WA. Difficulties in assigning human immunodeficiency virus-1 infection and seroreversion status in a cohort of HIV-exposed in children using serologic criteria established by the Centers for Disease Control and Prevention.Pediatrics. 1994;93(5):840–2. 8165094
9. World Health Organization. WHO recommendations on the diagnosis of HIV infection in infants and children. Geneva: World Health Organization; 2010 [cited 2017 Oct 20]. Available from: http://whqlibdoc.who.int/publications/2010/9789241599085_eng.pdf.
10. Burgard M, Blanche S, Jasseron C, Descamps P, Allemon MC, Ciraru-Vigneron N, et al. Performance of HIV-1 DNA or HIV-1 RNA tests for early diagnosis of perinatal HIV-1 infection during anti-retroviral prophylaxis. J Pediatr. 2012;160(1):60–7. doi: 10.1016/j.jpeds.2011.06.053 21868029
11. Sherman GG, Cooper PA, Coovadia AH, Puren AJ, Jones SA, Mokhachane M, et al. Polymerase chain reaction for diagnosis of human immunodeficiency virus infection in infancy in low resource settings. Pediatr Infect Dis J. 2005;24(11):993–7. 16282936
12. Kuhn L, Schramm D, Shiau S, Strehlau R, Pinillos F, Technau K, et al. Young age at start of antiretroviral therapy and negative HIV antibody results in HIV-infected children when suppressed. AIDS. 29(9):1053–60. doi: 10.1097/QAD.0000000000000677 25870988
13. Payne H, Mkhize N, Otwombe K, Lewis J, Panchia R, Callard R, et al. Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial. Lancet Infect Dis. 2015;15(7):803–9. doi: 10.1016/S1473-3099(15)00087-0 26043884
14. South Africa National Department of Health. National consolidated guidelines for the prevention of mother-to-child transmission of HIV (PMTCT) and the management of HIV in children, adolescents and adults. Pretoria: South Africa National Department of Health; 2015 [cited 2017 Oct 20]. Available from: https://aidsfree.usaid.gov/sites/default/files/tx_south-africa_pmtct_2015.pdf.
15. World Health Organization. WHO recommendations on the diagnosis of HIV infection in infants and children: annexes. Geneva: World Health Organization; 2010 [cited 2017 Nov 7]. Available from: http://apps.who.int/iris/bitstream/10665/44275/2/9789241599085_eng_Annexes.pdf.
16. World Health Organization. March 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2014 [cited 2017 Oct 20]. Available from: http://apps.who.int/iris/bitstream/10665/104264/1/9789241506830_eng.pdf?ua=1.
17. World Health Organization. Social, public health, human rights, ethical and legal implications of misdiagnosis of HIV status. Geneva: World Health Organization; 2016 [cited 2017 Nov 7]. Available from: http://www.who.int/hiv/pub/meetingreports/hiv-misdiagnosis-report/en/.
18. Shanks L, Klarkowski D, O’Brien DP. False positive HIV diagnoses in resource limited settings: operational lessons learned for HIV programmes. PLoS ONE. 2013;8(3):e59906. doi: 10.1371/journal.pone.0059906 23527284
19. Ciaranello AL, Morris BL, Walensky RP, Weinstein MC, Ayaya S, Doherty K, et al. Validation and calibration of a computer simulation model of pediatric HIV infection. PLoS ONE. 2013;8(12):e83389. doi: 10.1371/journal.pone.0083389 24349503
20. Ciaranello AL, Doherty K, Penazzato M, Lindsey JC, Harrison L, Kelly K, et al. Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age. AIDS. 2015;29(10):1247–59. doi: 10.1097/QAD.0000000000000672 25870982
21. Francke JA, Penazzato M, Hou T, Abrams EJ, MacLean RL, Myer L, et al. Clinical impact and cost-effectiveness of diagnosing HIV infection during early infancy in South Africa: test timing and frequency. J Infect Dis. 2016;214(9):1319–28. doi: 10.1093/infdis/jiw379 27540110
22. Kuhn L, Kroon M. Breastfeeding and the 2015 South African guidelines for prevention of mother-to-child transmission of HIV. S Afr J HIV Med. 2015;16(1):377.
23. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—explanation and elaboration: a report of the ISPOR Health Economic Evaluations Publication Guidelines Task Force. Value Health. 2013;16:231–50. doi: 10.1016/j.jval.2013.02.002 23538175
24. Statistics South Africa. Recorded live births: 2013. Statistical release P0305. Pretoria: Statistics South Africa; 2016 [cited 2017 Oct 23]. Available from: http://www.statssa.gov.za/publications/P0305/P03052013.pdf.
25. South Africa National Department of Health. The 2013 national antenatal sentinel HIV prevalence survey South Africa. Pretoria: South Africa National Department of Health; 2015 [cited 2017 Oct 23]. Available from: https://www.health-e.org.za/wp-content/uploads/2016/03/Dept-Health-HIV-High-Res-7102015.pdf.
26. World Health Organization. Early detection of HIV infection in infants and children: guidance note on the selection of technology for the early diagnosis of HIV in infants and children. Geneva: World Health Organization; 2007.
27. Feucht UD, Forsyth B, Kruger M. False-positive HIV DNA PCR testing of infants: implications in a changing epidemic. S Afr Med J. 2012;102(3 Pt 1):149–52.
28. Ciaranello AL, Lu Z, Ayaya S, Losina E, Musick B, Vreeman R, et al. Incidence of WHO stage 3 and 4 events, tuberculosis, and mortality in untreated, HIV-infected children enrolling in care before 1 year of age: an IeDEA (International Epidemiologic Databases To Evaluate AIDS) East Africa regional analysis. Pediatr Infect Dis J. 2014;33(6):623–9. doi: 10.1097/INF.0000000000000223 24378935
29. Violari A, Lindsey JC, Hughes MD, Mujuru HA, Barlow-Mosha L, Kamthunzi P, et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med. 2012;366(25):2380–9. doi: 10.1056/NEJMoa1113249 22716976
30. Palumbo P, Lindsey J, Hughes M. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med. 2010;363:1510–20. doi: 10.1056/NEJMoa1000931 20942667
31. Becquet R, Marston M, Dabis F, Moulton LH, Gray G, Coovadia HM, et al. Children who acquire HIV infection perinatally are at higher risk of early death than those acquiring infection through breastmilk: a meta-analysis. PLoS ONE. 2012;7(2):e28510. doi: 10.1371/journal.pone.0028510 22383946
32. Ciaranello AL, Perez F, Keatinge J, Park JE, Engelsmann B, Maruva M, et al. What will it take to eliminate pediatric HIV? Reaching WHO target rates of mother-to-child HIV transmission in Zimbabwe: a model-based analysis. PLoS Med. 2012;9(1):e1001156. doi: 10.1371/journal.pmed.1001156 22253579
33. Mallampati D, Ford N, Hanaford A, Sugandhi N, Penazzato M. Performance of virological testing for early infant diagnosis: a systematic review. J Acquir Immune Defic Syndr. 2017;75(3):308–14. doi: 10.1097/QAI.0000000000001387 28418986
34. Lilian RR, Kalk E, Bhowan K, Berrie L, Carmona S, Technau K, et al. Early diagnosis of in utero and intrapartum HIV infection in infants prior to 6 weeks of age. J Clin Microbiol. 2012;50(7):2373–7. doi: 10.1128/JCM.00431-12 22518871
35. Ciaranello AL, Park J-E, Ramirez-Avila L, Freedberg KA, Walensky RP, Leroy V. Early infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions. BMC Med. 2011;9:59. doi: 10.1186/1741-7015-9-59 21599888
36. Hsiao N-Y, Stinson K, Myer L. Linkage of HIV-infected infants from diagnosis to antiretroviral therapy services across the Western Cape, South Africa. PLoS ONE. 2013;8(2):e55308. doi: 10.1371/journal.pone.0055308 23405133
37. Sherman GG, Lilian RR, Bhardwaj S, Candy S, Barron P. Laboratory information system data demonstrate successful implementation of the prevention of mother-to-child transmission programme in South Africa. S Afr Med J. 2014;104(3):235–8.
38. Holmes C, Wood R, Badri M. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr. 2006;42:464–9. doi: 10.1097/01.qai.0000225729.79610.b7 16810113
39. Cleary S, Okorafor OA, Chitha W, Boulle A, Jikwana S. Financing antiretroviral treatment and primary health care services. S Afr Health Rev. 2005;58–74.
40. World Health Organization. Cost effectiveness and strategic planning (WHO-CHOICE). Geneva: World Health Organization; 2017 [cited 2017 Oct 31]. Available from: http://www.who.int/choice/en/.
41. World Health Organization. Tables of costs and prices used in WHO-CHOICE analysis. Geneva: World Health Organization; 2017 [cited 2017 Oct 31]. Available from: http://www.who.int/choice/costs/en/.
42. Clinton Health Access Initiative. 2015 antiretroviral (ARV) CHAI reference price list. Boston: Clinton Health Access Initiative; 2015 [cited 2017 Nov 7]. Available at: http://www.clintonhealthaccess.org/content/uploads/2016/01/2015-CHAI-ARV-Reference-Price-List.pdf.
43. Doherty K, Essajee S, Penazzato M, Holmes C, Resch S, Ciaranello A. Estimating age-based antiretroviral therapy costs for HIV-infected children in resource-limited settings based on World Health Organization weight-based dosing recommendations. BMC Health Serv Res. 2014;14(1):201.
44. Iliff PJ, Piwoz EG, Tavengwa NV, Zunguza CD, Marinda ET, Nathoo KJ, et al. Early exclusive breastfeeding reduces the risk of postnatal HIV-1 transmission and increases HIV-free survival. AIDS. 2005;19(7):699–708. 15821396
45. Lilian RR, Johnson LF, Moolla H, Sherman GG. A mathematical model evaluating the timing of early diagnostic testing in HIV-exposed infants in South Africa. J Acquir Immune Defic Syndr. 2014;67(3):341–8. doi: 10.1097/QAI.0000000000000307 25118910
46. Kilewo C, Karlsson K, Ngarina M, Massawe A, Lyamuya E, Swai A, et al. Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study. J Acquir Immune Defic Syndr. 2009;52(3):406–16. doi: 10.1097/QAI.0b013e3181b323ff 19730269
47. Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, Moffat C, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med. 2010;362(24):2282–94. doi: 10.1056/NEJMoa0907736 20554983
48. Kesho Bora Study Group, de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis. 2011;11(3):171–80. doi: 10.1016/S1473-3099(10)70288-7 21237718
49. Tonwe-Gold B, Ekouevi DK, Viho I, Amani-Bosse C, Toure S, Coffie PA, et al. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach. PLoS Med. 2007;4(8):e257. doi: 10.1371/journal.pmed.0040257 17713983
50. Fawzi W, Msamanga G, Hunter D, Renjifo B, Antelman G, Bang H. Randomized trial of vitamin supplements in relation to transmission of HIV-1 through breastfeeding and early child mortality. AIDS. 16(14):1935–44. 12351954
51. Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet. 2002;359(9313):1178–86. doi: 10.1016/S0140-6736(02)08214-4 11955535
52. Leroy V, Karon J, Alioum A, Ekpini E, Meda N, Greenberg A. Twenty-four month efficacy of a maternal short-course zidovudine regimen to prevent mother-to-child transmission of HIV-1 in West Africa. AIDS. 2002;16(4):631–41. 11873008
53. Chigwedere P, Seage G, Lee T, Essex M. Efficacy of antiretroviral drugs in reducing mother-to-child transmission of HIV in Africa: a meta-analysis of published clinical trials. AIDS Res Hum Retroviruses. 2008;24(6):827–37. doi: 10.1089/aid.2007.0291 18544018
54. Scott GB, Brogly SB, Muenz D, Stek AM, Read JS, International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) P1025 Study Team. Missed opportunities for prevention of mother-to-child transmission of human immunodeficiency virus. Obstet Gynecol. 2017;129(4):621–8. doi: 10.1097/AOG.0000000000001929 28277349
55. Dabis F, Bequet L, Ekouevi DK, Viho I, Rouet F, Horo A, et al. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS. 2005;19(3):309–18. 15718842
56. Thior I, Lockman S, Smeaton LM, Shapiro RL, Wester C, Heymann SJ, et al. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana. JAMA. 2006;296(7):794. doi: 10.1001/jama.296.7.794 16905785
57. Peltier CA, Ndayisaba GF, Lepage P, van Griensven J, Leroy V, Pharm CO, et al. Breastfeeding with maternal antiretroviral therapy or formula feeding to prevent HIV postnatal mother-to-child transmission in Rwanda. AIDS. 2009;23:2415–23. doi: 10.1097/QAD.0b013e32832ec20d 19730349
58. Palombi L, Marazzi MC, Voetberg A, Magid NA. Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV. AIDS. 2007;21(Suppl 4):S65–71.
59. Thomas T, Masaba R, Borkowf C, Ndivo R, Zeh C, Misore A. Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding—the Kisumu Breastfeeding Study, Kenya: a clinical trial. PLoS Med. 2011;8(3):e1001015. doi: 10.1371/journal.pmed.1001015 21468300
60. Vyankandondera J, Luchters S, Hassink E. Reducing risk of HIV-1 transmission from mother to infant through breastfeeding using antiretroviral prophylaxis in infants (SIMBA study). Abstract number LB7. 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment; 2003 Jul 13–17; Paris, France.
61. Chasela C, Hudgens M, Jamieson D, Kayira D, Hosseinipour M, Kourtis A. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med. 2010;362(24):2271–81. doi: 10.1056/NEJMoa0911486 20554982
62. Kuhn L, Aldrovandi GM, Sinkala M, Kankasa C, Semrau K, Mwiya M, et al. Effects of early, abrupt weaning on HIV-free survival of children in Zambia. N Engl J Med. 2008;359(2):130–41. doi: 10.1056/NEJMoa073788 18525036
63. Kuhn L, Aldrovandi G, Sinkala M, Kankasa C, Mwiya M, Thea D. Potential impact of new WHO criteria for antiretroviral treatment for prevention of mother-to-child HIV transmission. AIDS. 2010;24(9):1374–7. 20568677
64. World Health Organization. New strategies for infant HIV diagnosis: expert review meeting. Geneva: World Health Organization; 2013 Sep 18–19.
65. Hsiao N-Y, Dunning L, Kroon M, Myer L. Laboratory evaluation of the Alere q point-of-care system for early infant HIV diagnosis. PLoS ONE. 2016;11(3):e0152672. doi: 10.1371/journal.pone.0152672 27032094
66. Jani IV, Meggi B, Mabunda N, Vubil A, Sitoe NE, Tobaiwa O, et al. Accurate early infant HIV diagnosis in primary health clinics using a point-of-care nucleic acid test. J Acquir Immune Defic Syndr. 2014;67(1):e1–4. doi: 10.1097/QAI.0000000000000250 24933096
67. Babiker A, Castro nee Green H, Compagnucci A, Fiscus S, Giaquinto C, Gibb D. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis. 2011;11(4):273–83. doi: 10.1016/S1473-3099(10)70313-3 21288774
68. Losina E, Yazdanpanah Y, Deuffic-Burban S, Wang B, Wolf LL, Messou E, et al. The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Cote d’Ivoire. Antivir Ther. 2007;12(4):543–51. 17668563
69. Thomas LS. Costing of HIV/AIDS services at a tertiary level hospital in Gauteng Province [thesis]. Witwatersrand: University of Witwatersrand; 2006 [cited 2017 Oct 23]. Available from: http://wiredspace.wits.ac.za/handle/10539/2008.
70. Bassett I V, Giddy J, Nkera J, Wang B, Losina E, Lu Z, et al. Routine voluntary HIV testing in Durban, South Africa: the experience from an outpatient department. J Acquir Immune Defic Syndr. 2007;46(2):181–6. doi: 10.1097/QAI.0b013e31814277c8 17667332
71. Briggs A, Weinstein M, Fenwick E. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–6. Value Health. 2012;15:835–42. doi: 10.1016/j.jval.2012.04.014 22999133
72. Feucht U, Thomas W, Forsyth B, Kruger M. Incorrectly diagnosing children as HIV-infected: experiences from a large paediatric antiretroviral therapy site in South Africa. SAJCH. 2012;6(3):72–5.
73. Kachega S, Okoth V, Kadima S, Vihenda S, Okapesi E, Nyambura E, et al. Discrepant test findings in early infant diagnosis of HIV in a national reference laboratory in Kenya: challenges and opportunities for programs. J Trop Pediatr. 2012;58(4):247–52. doi: 10.1093/tropej/fmr076 22052701
74. Dube Q, Dow A, Chirambo C, Lebov J, Tenthani L, Moore M, et al. Implementing early infant diagnosis of HIV infection at the primary care level: experiences and challenges in Malawi. Bull World Health Organ. 2012;90(9):699–704. doi: 10.2471/BLT.11.100776 22984315
75. Dahourou D, Amorissani-Folquet M, Coulibaly M, Avit-Edi D, Meda N, Timite-Konan M. Missed opportunities of inclusion in a cohort of HIV-infected children to initiate antiretroviral treatment before the age of two in West Africa, 2011 to 2013. J Int AIDS Soc. 2016;19(1):20601. doi: 10.7448/IAS.19.1.20601 27015798
76. Feucht UD, Meyer A, Thomas WN, Forsyth BWC, Kruger M. Early diagnosis is critical to ensure good outcomes in HIV-infected children: outlining barriers to care. AIDS Care. 2016;28(1):32–42. doi: 10.1080/09540121.2015.1066748 26273853
77. Gibb D, Duong T, Leclezio VA, Walker AS, Verweel G, Dunn DT, et al. Immunologic changes during unplanned treatment interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 infection. Pediatr Infect Dis J. 2004;23(5):446–50. 15131469
78. Wamalwa D, Benki-nugent S, Langat A, Tapia K, Ngugi E, Moraa H, et al. Treatment interruption after 2-year antiretroviral treatment (ART) initiated during acute/early HIV in infancy: a randomized trial. AIDS. 2016;30(15):2303–13. doi: 10.1097/QAD.0000000000001158 27177316
79. Bhattacharya R, Barton S, Catalan J. When good news is bad news: psychological impact of false positive diagnosis of HIV. AIDS Care. 2008;20(5):560–4. doi: 10.1080/09540120701867206 18484325
80. World Health Organization. WHO validates countries’ elimination of mother-to-child transmission of HIV and syphilis. Geneva: World Health Organization; 2016 [cited 2017 Nov 7]. Available from: http://www.who.int/mediacentre/news/statements/2016/mother-child-hiv-syphilis/en/.
81. World Health Organization. WHO validates elimination of mother-to-child transmission in Cuba. Geneva: World Health Organization; 2015 [cited 2017 Nov 7]. Available from: http://www.who.int/mediacentre/news/releases/2015/mtct-hiv-cuba/en/.
82. Sherman G. HIV testing during the neonatal period. S Afr J HIV Med. 2015;16(1):2–4.